Altachem Pharma Ltd. announces reconstituted Scientific Advisory Board

- Multidisciplinary, international team of experts convened to advise 
management -

Trading Symbol: AAF:TSX Venture Exchange

EDMONTON, Aug. 24 /CNW/ - Altachem Pharma Ltd. ("Altachem" or "The
Company") today announces that it has reconstituted its Scientific Advisory
Board to better reflect its current strategy of focus on cancer therapies.
Returning members Dr. Bill Lown and Dr. Sam Abraham are joined by
Dr. Ron Moore, Dr. Gilles Lauzon and Dr. Ki-Jun Hwang.
"I'm delighted that we have been able to assemble such a high-powered
team of prestigious individuals to help develop and execute the Company's
scientific strategy," said Dr. Selvaraj Naicker, Interim COO of Altachem.
"While we have known and interacted with most of these scientists for quite
some time on a one-on-one basis, we have never before convened them as a team.
I'm excited to imagine what could be accomplished by this group working in
unison with Altachem's management".
The bios for the new Scientific Advisory Board are as follows (in
alphabetical order):

Samuel Abraham, PhD

Dr. Abraham is the Director of the Technology Development Office at the
BC Cancer Agency. He received his PhD in Genetics from the University of
British Columbia. He joined Inflazyme Pharmaceuticals as a senior scientist in
1996, and later became Project Leader for the Transplant program, as well as
Division Leader for Cell and Molecular Biology. Having a well-grounded
knowledge of the local as well as international bio-tech arena, Dr. Abraham
has the ability to understand and thus place a particular invention before the
appropriate potential industrial partner. Dr. Abraham's ability to integrate,
present and effectively communicate complex scientific issues to business as
well as a variety of investors will be very helpful to Altachem as it's
programs move beyond the R&D stage.

Ki-Jun Hwang, PhD

Dr. Hwang is the Director of the Centre for Research in Bioactive
Materials at the Chonbuk National University in Korea and a full professor at
that University. He received his PhD in Organic Chemistry from the University
of Washington in 1981. He has researched and published extensively in the
field of bioactive chemistry and is the author of over 60 papers in refereed
journals as well as 34 patents and patent applications. He is also the
inventor of 'Flupyrazophos', the first agrochemical invented and developed in
Korea. Dr. Hwang brings deep knowledge and expertise to the Company's CDK
inhibitor program, as well as to the chemistry aspects of Altachem's
Photodynamic Therapy products.

Gilles Lauzon, PhD, MD, FRCP(C)

Dr. Lauzon is Associate Professor and Director, Division of Dermatology
in the Department of Medicine at the University of Alberta. He holds MSc and
PhD degrees in Pharmacology (University of Alberta) as well as a Medical
Degree from the University of Calgary. He is involved in numerous clinical
research studies addressing psoriasis, atopic dermatitis, vitiligo, herpes
simplex infections and warts. His area of clinical expertise is geriatric
dermatology, with special interest in long-term care. Dr. Lauzon also acts as
Chair, Dermatology Examination Board, Royal College of Physicians and Surgeons
of Canada (2002-2005). He participates in numerous committees of the
Department of Medicine and Faculty of Medicine (University of Alberta), and
the Canadian Dermatology Association. Dr. Lauzon brings key expertise to the
Company in the development of its topical Photodynamic Therapy products.

J. William Lown, PhD, DIC

Professor Lown is Emeritus Professor of Chemistry at the University of
Alberta and has been a faculty member in Chemistry since 1964. He has held the
positions of Alberta Heritage Foundation for Medical Research Professor-in-
Residence during 1984-1985 and of McCalla Research Professor in 1988. Dr. Lown
has published over 400 refereed research articles mainly in the field of
cancer chemotherapy. Dr. Lown was awarded the Paul Erilch Prize for 1992 by
the Association de Recherche Scientifique Paul Neumann for his work in
chemotherapy and was elected Fellow of the International Union Against Cancer
in 1992. Dr. Lown was awarded the Hoffman-La Roche Prize for Medicinal
Chemistry for 1996 by the Canadian Society for Chemistry, and was named Killam
Professor in September 1996. Dr. Lown has been actively researching the
Hypocrellin molecules (the platform molecules for Altachem's Photodynamic
Therapy projects) since 1993 and has been a close collaborator of the Company
for a number of years.

Ron Moore, MD, PhD, FRCSC, FACS

Dr. Ron Moore is an Alberta Heritage Scholar and is Professor of Surgery
and Oncology in the Faculty of Medicine and Dentistry at the University of
Alberta. He is a noted urological surgeon, specializing in oncology and
transplantation. Dr. Moore is the author of over 45 papers in refereed
journals, many of which are in the field of Photodynamic Therapy. Dr. Moore,
in collaboration with Dr. John Tulip at the University of Alberta is leading
the clinical and preclinical development work on the Company's Photodynamic
Therapy candidate for prostate cancer. Dr. Moore has been actively engaged in
PDT research since 1991.

About Altachem Pharma Ltd

Altachem is a publicly traded (TSX Venture Exchange: AAF), Alberta-based
pharmaceutical company committed to the development and commercialization of
new pharmaceutical products. It is developing a series of products for the
treatment of cancer and other proliferative diseases based on its SonoLight
and CDK platforms. It also has a profitable product in Accu-MAb(TM), a
monoclonal-based diagnostic kit for whooping cough.
Except for historical information, this press release may contain 
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

  "TSX Venture Exchange has neither approved nor disapproved of the
                   information contained herein."

%SEDAR: 00008400E